絞り込み

16646

広告

[Rituximab in the treatment of indolent non-Hodgkin's lymphoma].

著者 Aurer I , Mitrović Z , Radman I , Kovacević-Metelko J , Nemet D , Serventi-Seiwerth R , Stern-Padovan R , Jakic-Razumović J , Nola M , Zupancić-Salek S , Sertić D , Labar B
Lijec Vjesn.2004 Nov-Dec ; 126(11-12):307-11.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

Zavod za hematologiju, Klinika za unutarnje bolesti Medicinskog fakulteta i Klinickoga bolnickog centra, Zagreb.

スターを付ける スターを付ける     (26view , 0users)

Medical

Miscellaneous

Indolent Non-Hodgkin's lymphomas (NHL) are a group of slowly progressive immune system malignancies that cannot be cured with conventional treatment. Rituximab is an anti-CD20 monoclonal antibody that has recently become a part of the standard treatment of B-cell lymphoid malignancies. Here we present our experience in 25 patients with indolent NHL treated with rituximab with or without chemotherapy. Rituximab was administered at 3-4 week intervals in the standard dose of 375 mg/m2. 88% of the patients responded, 16 achieved a complete and 6 partial remission. Estimated 2-year actuarial survival is 63%. Response and survival rates were significantly better in patients with favorable prognosis (lower IPI score). Adverse effects related to rituximab occurred in 2 patients and were mild. Our results are completely comparable to previously reported studies and show that rituximab is effective and safe for the treatment of indolent B-cell NHL.
PMID: 16082888 [PubMed - indexed for MEDLINE]
印刷用ページを開く Endnote用テキストダウンロード